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ABSTRACT 

An effective AIDS vaccine must control highly diverse circulating strains of HI V­
I. Among HIV -I gene products, the envelope (Env) protein contains variable as well as 
conserved regions . In this report, an informatic approach to the design of T-cell vaccines 
directed to HIV -I Env M group global sequences was tested. Synthetic Env antigens 
were designed to express mosaics that maximize the inclusion of common potential T­
cell epitope (PTE) 9-mers and minimize the inclusion of rare epitopes likely to elicit 
strain-specific responses. DNA vaccines were evaluated using intracellular cytokine 
staining (ICS) in inbred mice with a standardized panel of highly conserved 15-mer PTE 
peptides. I, 2 and 3 mosaic sets were developed that increased theoretical epitope 
coverage. The breadth and magnitude ofT-cell immunity stimulated by these vaccines 
were compared to natural strain Env's; additional comparisons were performed on mutant 
Env's, including gpl60 or gpl45 with or without V regions and gp41 deletions. Among 
them, the 2 or 3 mosaic Env sets elicited the optimal CD4 and CD8 responses. These 
responses were most evident in CD8 T cells; the 3 mosaic set elicited responses to an 
average of 8 peptide pools compared to 2 pools for a set of3 natural Env's. Synthetic 
mosaic HIV -I antigens can therefore induce T-cell responses with expanded breadth and 
may facilitate the development of effective T -cell-based HIV -I vaccines. 
INTRODUCTION 

The development of AIDS vaccines has been advanced recently by 
demonstrations of increased survival and decreased viral load following vaccination with 
T-cell vaccines in non-human primate models (12,19,23,26,31,37). Although such 
vaccine studies have implied that T cells may contribute to the control of viremia in the 
highly lethal SIVmac25I challenge model, the applicability of these results in human 
studies remains uncertain. The major concern regarding the efficacy of HIV vaccines in 
humans is the extraordinary genetic diversity of the virus. The sequence similarity of 
HIV -I envelope from diverse isolates within a clade can diverge as much as 15%, and 
between alternative clades may approach 30% (10). In addition, the diversity of the viral 
Gag gene product can approach similar levels, particularly in p 17 and p 15, which are 
much more diverse than p24 (6), although Gag does not have the extreme localized 
diversity seen in the highly variable regions of Env (6, I 0). While the approach to viral 
diversity has been addressed in existing vaccines through the use of envelopes derived 
from representative viruses in the major clades, increasing knowledge about the genetic 
diversity of naturally occurring isolates has enabled alternative approaches that enhance 
population coverage of vaccine-elicited T-cell responses. 
Approaches under consideration include the use of central gene sequences based 
on ancestral, consensus, or center of the tree genetic analyses (5, I 0,18,31,36). Such 
prototypes are derived by selection of the most common amino acids at each residue 
(10,16,17,21,25,36), identifying the most recent common ancestor of diverging viruses in 
a vaccine target population (5, 10,18,36), or modeling the sequence at the center of the 
phylogenetic tree (29), respectively. Peptides based on any of these three centralized 
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protein strategies enhanced the detection of T-cell responses in natural infection relative 
to the use of pep tides based on natural strains; however, all three strategies behaved 
equivalently (7). 
The use of a single M group consensus/ancestral Env sequence has been shown to 
elicit T-cell responses with greater breadth of cross-reactivity than single natural strains 
in animal models (31,36). Such central sequences do not exist in nature, and even 
phylogenetic ancestral reconstructions are just an approximate model of an ancestral state 
of the virus (8). Thus, central sequence strategies have provided evidence that various 
informatically-derived gene products can elicit immune responses to T-cell epitopes 
found in diverse circulating strains, leading to the possibility of using computational 
strategies to design polyvalent vaccines which optimize T-cell coverage (6,24). In this 
study, we have evaluated for the first time the ability of non-natural mosaic Env 
immunogens (6) to elicit T-cell responses of increased cross-reactivity against epitopes 
represented in naturally circulating viruses in animals. 
Mosaic HIV -1 envelope genes were derived using an informatic approach, 
whereby in silica generated recombinants of natural variants from the Los Alamos 
database M group Env alignment were created, scored, and selected in combination to 
optimize the coverage of9-mers in the global database for a given vaccine cocktail size. 
While mosaic proteins are artificial constructs that do not occur in nature, they align well 
to natural proteins, and any short span found in mosaics will tend to be found repeatedly 
among natural strains (although some of the hypervariable loop regions of Env are so 
extremely variable that they are not repeated among circulating strains, and necessitate 
bridging these regions with segments found in a single strain). In silica recombination 
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breakpoints are constrained to create fusion points found in natural sequences. It is 
possible to provide increased breadth of coverage with a single mosaic, providing the 
maximum possible single-antigen diversity coverage for stretches of 9 amino acids. 
Alternatively, mUltiple mosaics can increase the breadth of representation but have the 
drawback of requiring the synthesis of additional vectors for clinical use. Mosaics also 
preserve a natural Env-like sequence to retain normal antigen processing. Here, we have 
compared single, double or triple mosaic envelope antigen sets to naturally circulating 
strains or other derivatives for their ability to elicit immune responses of increased 
breadth. The data suggest that mosaic HIV -1 envelope sequences provide an approach 
that may be useful in the development of HI V vaccines that respond to T-cell epitopes 
represented in naturally circulating strains. 
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MATERIALS AND METHODS 

Immunogens 
Plasmid DNAs containing five different modifications of the canonical Env gene 
were generated for each of the antigen sets used in this study: full length Env proteins 
("gp 160"), and four variants with short deletions. Deletion variants were as follows: 1) 
the full length Env protein with variable loops 1,2,4 and 5 deleted, Env gpI60~Vs; 2) 
the full length Env protein with deletion of the fusion domain, the cleavage domains, and 
shortened interspace between heptad 1 (H 1) and heptad 2 (H2) (4), Env gp 160~CFI; 3) 
the full length Env protein with deletion of the fusion domain, the cleavage domains, 
sh0l1ened interspace between heptad 1 (HI) and heptad 2 (H2), and also with variable 
loops 1,2,4 and 5 deleted, Env gpI60~CFMVs; and 4) the Env protein without 
cytoplasmic domain, with deletion of the fusion domain, the cleavage domains, shortened 
interspace between heptad 1 (HI) and heptad 2 (H2), and also with variable loops 1,2,4 
and 5 deleted (Env gpI45~CFMVs FI, F2, F3, F4). All modified HIV Env genes were 
synthesized using human-preferred codons (GeneArt, Regensburg, Germany) (15) or by 
preparation of oligonucleotides of 75 bp overlapping by 25 or of 60 bp overlapping by 20 
and assembled by Pwo (Boehringer Mannheim) and Turbo Pfu (Stratagene) as described 
previously (4,14). All deletions or other modifications were generated by site-directed 
mutagenesis using a QuickChange kit (Stratagene, La Jolla, CA). The cDNAs were 
cloned into a plasmid expression vector, pCMV IR, which mediates high level expression 
and immunogenicity in vivo (2,38). 
Mosaic proteins were designed using the methods described in Fischer et al. (6); a 
web-based suite of tools is now available that enables generation of candidate mosaic 
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sequences for any set of variable pathogen proteins, and epitope length sequence 
coverage comparison of different vaccine antigen candidates (34). Mosaics are optimized 
as a set for a particular size of cocktail, so were designed separately for the 1,2, and 3 
antigen combinations (i.e., the single mosaic is not found in the 2 or 3 mosaic set). The 
input data was an unaligned version of the full Env M group alignment from the Los 
Alamos National Laboratory HIV database, as of July 2006 (restricted to include a single 
sequence per person). Sequences were generated as recombinants of that set, and optimized 
for 9-mer coverage of that set. Unnatural breakpoints were excluded. We also selected the 
3 natural sequences that in combination provided the optimal 9-mer coverage of that same 
data set, either with or after exclusion of the V-loops, using the same software suite (9,34) 
(http://www.hiv.lanl.gov/contentJsequence/MOSAIC). The length of 9 amino acids was 
selected for the optimization criteria because it is the most common length of optimal CD8 
epitopes; nearby lengths (8,10,11,12 ...) also get greatly enhanced coverage through the 
process of optimizing on 9-mers (data not shown). The full length Env protein amino acid 
sequences of the three sets of mosaics, gp 160 and various mutants, are shown (Fig. S 1). 
Vaccine antigen comparisons 
The basic antigen design strategies included the following sets: 3 natural strains 
that have been previously studied as a polyvalent vaccine in the modified form 
gp145~CFI, each from different clades (Env ABC); 1,2, or 3 gpI60 mosaics (mos.I, 
mos.2, mos.3); 3 natural strains selected to in combination provide optimal M group 
coverage of gp160 9-mers (nat.3) (CRFOIAE, FIN92I68 AF2I9267; clade B, QH0908 
AF277072; and clade C, 93IN1OI AB023804; listed as clade, sequence name and 
accession number), or to provide optimal M group coverage if the V regions were 
excluded (nat~V.3): clade C, 99BW46424 AF443084; clade B, QH0908 AF277072; 
clade A, KNH 1088 AF457063. These baseline sets were further modified to enable 
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direct comparisons of T-cell responses of the full gp 160 proteins to previously studied 
envelope modifications; thus, gp160 responses for a given antigen set were compared to 
gp145~CFI and gp160~CFI modifications. A negative control (negc) consisting only of 
the CMV IR vector was included. 
Splenocytes from immunized mice were analyzed by intracellular cytokine 
staining (ICS) for TNF -a and IFN-y T-cell responses against the approximately 100 
different peptide pools described below. Responses from CD4+ and CD8+ T lymphocytes 
were measured separately. The data were analyzed for the magnitude of overall response 
(strength) and the number of positive responses (breadth). Both TNF-o. and IFN-y 
responses were measured and analyzed. IL-2 responses were also measured, but there 
was very little signal and the measurements were dominated by noise, and so these were 
not included in further analysis. Between 7 and 10 vaccine antigen/protein modifications 
(vac/mod) configurations were tested on 12 separate days. The 12 sets of experiments 
were grouped into six pairs; in each pair, the same set of antigen configurations was 
tested. The magnitude of the overall responses varied by a factor of up to about six on 
different days, and this effect was corrected through statistical methods, as described 
below. Not all configurations of vaccine plus modification were tested, and the number 
of times a particular configuration was repeat tested ranged from 2 to 12. In Table S 1, 
we indicate the number of micro titer plates measured for each vector. 
Vaccination 
Six- to eight-week-old B6D2FlIJ (H2 Haplotype bid) female mice (Jackson 
Laboratory, Bar Harbor, ME) were used for these immunogenicity studies. Mice (ten per 
group) were immunized with a total of 15 Ilg of DNA (l00 ilL in PBS), 4x at two-week 
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intervals. Immunizations were administered bilaterally into the muscle of the hind leg 
using needle and syringe. The groups included pCMVIR with no insert (Control); 
vaccines containing 15 /-lg of 1 mosaic plasmid DNA; 7.5 /-lg of each plasmid in the two­
plasmid groups, e.g. a combination of 2 mosaics; or 5 /-lg of each plasmid in the three­
plasmid groups, e.g. 3 mosaics, Natural-Strains(Setl), Natural-Strains(Set2), and 
Trivalent. All animal experiments were reviewed and approved by the Animal Care and 
Use Committee, Vaccine Research Center (VRC), National Institute of Allergy and 
Infectious Diseases (http://www.niaid.nih.gov/vrc) and performed in accordance with all 
relevant federal and National Institutes of Health guidelines and regulations. 
Peptides for ICS stimulation 
In this study, we used 492 Env peptides for intracellular cytokine staining (ICS) 
stimulation. For this ICS analysis, 15 mer PTE peptides (20) were used to evaluate the 
vaccines as the common standardized panel of HIV-1 peptides for T -cell-based vaccines. 
The 492 Env peptide sequence set was designed to permit expression of the potential T­
cell epitopes (PTE) found most frequently in the sequences of circulating worldwide 
HIV-1 strains, based on 549 full-length HIV -1 genome sequences obtained from the Los 
Alamos National Laboratory (LANL) HIV sequence database as of February 2005. All 
synthesized peptides (New England Peptide, Gardner, MA) are 15 a.a. in length with 
naturally occurring 9 a.a. sequences that are potential T-cell determinants captured in an 
unbiased manner (20,22). Briefly, frequencies were computed for all 9-amino-acid 
subsequences in the dataset, and then l5-mer peptides were selected in order of the 
summed frequencies of the previously unincluded 9-mers they contained, using a forward 
stepwise algorithm. This algOlithm selects first for the highly conserved PTEs, then the 
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less conserved. 492 PTE peptides were generated (for a coverage threshold of 15% (20)), 
and grouped into 78 pools of 6 to 12 PTE 15-mer peptides such that the peptides that 
carried the highest frequency 9-mers were grouped in the first pool, continuing so that the 
peptides with the rarest 9-mers were in the 78th pool. All but the pools representing the 
rarest potential epitopes contained 6 peptides each; the 3 pools of rarest potential epitopes 
contained 10-12 peptides. We refer to these sets as PTE pools. Four pools with larger 
numbers of peptides were also tested, with 114 for the first 3 large pools, 148 for the 4th 
large pool; we refer to these sets as PTE superpools. Pooled sets of peptides, 15-mers 
overlapping by 11, corresponding to each of the three Envelopes included in the Env 
ABC polyvalent vaccine were also used as previously described (2-4,6,14,32). 
Cellular Immune Analysis 
Two weeks after the last immunization, spleens from 3 mice in each group were 
harvested aseptically, gently homogenized to form a single-cell suspension, washed, and 
resuspended to a final concentration of approximately 107 cells/ml. All groups of 
harvested spleen cells (maximum of 106 cells/peptide pool) were stimulated for 5 h in the 
presence of 2 Ilg of anti-CD28 and anti-CD49d mAbs/ml (BD PharMingen, San Diego, 
CA), and also with 10 Ilglml brefeldin A (Sigma, St. Louis, MO). Cells were stimulated 
for 5 hours with a) 15-mers of 6-peptide pools or 12-peptide pools of PTE, as the target 
testing stimulating agents, b) no stimulation for background control, c) Ebola OP protein 
as the negative control, and d) phorbol myristate acetate (PMA) with ionomycin as the 
positive control. Env A, Env B, and Env C pools derived from three candidate genes 
previously described (4) were included as additional controls. Cells were then washed 
and stained with Vivid dye (Invitrogen, Carlsbad, CA) to determine their viability. FC 
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block monoclonal antibodies were added to the cells followed by staining with surface 
antigens (rat anti-mouse cell surface antigens CD3-PerCP-Cy5.5, CD4-AlexaFluor700 
and CD8-APC-Cy7, BD PharMingen, San Diego, CA). The cells were washed again, 
perrneabilized, fixed with CytofixlCytoperrn and stained with monoclonal antibodies (rat 
anti-mouse cell surface antigens CD3-PerCP-Cy5.5, CD4-AlexaFluor700 and CD8-APC­
Cy7, and rat anti-mouse cytokines IFN-y-APC, IL-2-PE, and TNF-a-PE-Cy7, BD 
PharMingen, San Diego, CA) followed by multi-parametric flow cytometry analysis to 
detect the IFN-y, IL-2, or TNF-a positive cells in the CD4+ or CD8+ T-cell population. 
Another 3 mice in each group were subjected to the same analysis two days after the 
initial test to repeat the analysis. 
Flow Cytometry 
Stained cells were assayed on the BDTM LSR-II Flow Cytometer using F ACSDiva 
software (BD Biosciences, San Jose, CA). The data were analyzed with FlowJo 8.6.1 
software (Tree Star, Ashland, OR). 
Statistical Methods 
The objective of the analysis is to compare the strength and breadth of different 
vaccine strategies and Envelope modifications. A statistical model was used that enabled 
us to control for the variability between assays done on different days (we will call this 
the "date effect"), and so to assess the contribution of the vaccine strategy (the "vaccine 
effect") to the outcome. These effects should be independent, since the date effect will 
depend on the measurement process and the variation between mice, and the vaccine 
effect will depend on the vaccine that was given. The usual procedure for dealing with 
such independent effects is to adopt a balanced experimental design, so that the 
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measurement of a particular vaccine is randomized over the different dates. However, 
the adoption of such a design was inconsistent with the exploratory manner in which the 
data was acquired, and in any case, the significance of the date effect was not fully 
recognized in advance. It turns out that the strength of the different vaccines varies 
substantially, by a factor of about six, but the date effect is roughly comparable in 
magnitude, complicating the assessment of both strength and breadth. 
While some vaccines were repeated many times, other vaccines were only 
measured on a few days, often only two. If, for example, the overall response to the 
vaccine was low, it was not clear whether this was due to the vaccine or to the day on 
which it was measured. The date effect also complicated the assessment of breadth. If 
we had used a fixed threshold to assess positivity, as is customary, we would have missed 
positive responses on days when the overall response was low, and interpreted random 
noise as a positive response on days when the overall response was high. We tested this 
approach, and found great variation in the number of positives for the same vac/mod on 
different days. A routine analysis, not correcting for the date effect, would have led to 
greatly increased noise in the breadth assessments and would have prevented us from 
making meaningful comparisons. 
To deal with this problem, we adopted a statistical model that enabled us to 
correct for the date effect. We call the corrected data the "date-corrected" data. Using 
the date-corrected data, we can compare vaccine strengths directly, and use a common 
threshold for assessing positivity. Because the date effect is uncertain, the date-corrected 
data acquires some additional uncertainty, but the results are nevertheless highly 
significant. Intuitively, what makes this approach possible is that some of the vaccines 
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were tested on most or all of the dates, and the difference in their responses provides the 
necessary information about the date effect. 
In order to account for the date effect, we modeled the logarithm of the vaccine 
strength, rather than the strength itself; this converts the multiplicative variation into an 
additive variation that can then be estimated using a linear model. Accordingly, the 
following "two-way layout" was adopted: 
lij = Vi + dj + Q' (1) 
where I. . is the (natural) logarithm of the strength of the responses for the vac/mod i on 
I) 
day j, v . and d. are quantifications of the vaccine and date effects, respectively, in this 
1 J 
model, and the £ .. are identical and independently distributed Gaussian random errors, to 
I) 
account for natural mouse-to-mouse variation and other stochastic effects. We describe 
how we determined l.. below. Note that the log-response is additive in v. and d., which 
I) I J 
reflects the independence of the date and vaccine effects. 
We use the data l.. to make estimates, v. and d., for the vaccine and date effects. 
I) I J
The interpretation of these numbers, roughly speaking, is the following: Ifvaccines 1 and 
2 are measured on the same day, then we expect the response to vaccine 1 to be 
exp(V.)/exp(v2) times larger than the response to vaccine 2. Similarly, if the same 
vaccine is measured on day 1 and day 2, then we expect the response on day 1 to be 
exp(d,) I exp(d2 ) times larger than the response on day 2. The analysis only gives ratios 
of the strengths (or differences in the log strengths). Thus, we measure all vaccine 
strengths relative to the negative control, and all date effects relative to an arbitrarily 
chosen fiducial date. 
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experiments were also performed testing IL-2 responses, but the results were weak and 
sporadic and thus excluded from further analyses. We then used a standard 
agglomerative clustering algorithm (35), using Euclidean distances, to cluster the 
experiments (row vectors) and the peptide pools (column vectors) 
(http://www.hiv.lanl.gov/contentiseguence/HEATMAPlheatmap.html. based on the R 
package heatmap.2). These cluster patterns are shown on the margins of the heatmaps 
(Fig. 6), which were generated by color-coding responses to indicate those that generated 
no response (pale yellow), 1 response to either TNF-a or IFN-"'l (orange) or responses to 
both (red). Statistical support for the various clusters is indicated on the dendrogram 
branch points, based on the approximately unbiased test of multistep-multi scale 
bootstraps (33). 
The data in these experiments came from a total of352 microtiter plates, each of 
which measured IFN or TNF responses to CD4+ or CDS+ T cells for a particular vaccine 
modality (vac/mod) on a particular day. By vac/mod we refer to the DNA vaccine 
antigen cocktails (including 1, 2 or 3 mosaics; 3 natural strains selected to provide in 
combination optimal 9-mer coverage; three natural strains, one each from clades A, B 
and c. ..) and the Env modifications (including gp160, gpI45L1CFI, gpI60L1CFI, and 
gpI45L1CFIL1Y and gpI45L1CFIL1Y, where L1Y refers to removal of the hypervariable 
loops, and L1CFI refers to deletions of the cleavage site, fusogenic domain, and spacing of 
heptad repeats I and 2 (4). In some cases, all or part of the data from a given plate was 
clearly affected by systematic error, as indicated by trends or consistently elevated 
responses from pools in contiguous regions of the plate. Such plates, of which 17 
involved CDS and two CD4, were left out of the analysis. Thus, a total of 333 plates 
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were used. Among these plates, there was also a very small fraction of small peptide 
pools (0.3%) for which data was unavailable. We did not try to estimate the missing 
data. 
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RESULTS 

Vaccine insert design 
Polyvalent mosaic vaccines were designed using a genetic algorithm (6) to 
assemble in silica recombinants of natural Env proteins with breakpoints that do not 
disrupt the protein and which optimize potential epitope coverage of a diverse population. 
All stretches of 9 amino acids (or 9-mers) were considered potential epitopes, and the 
presence of rare 9-mers was minimized. The M group sequence alignment from the 2006 
HIV database (www.hiv.lanJ.gov) was used as a baseline; M designates the "main" group 
of HIV-1 sequences that includes all of the standard clades (A-K) and their recombinants, 
the over-arching set of diverse HIV sequences responsible for the global HIV pandemic. 
We performed separate optimizations for 1, 2 or 3 mosaic gp 160 DNA vaccine 
antigen combinations. Each set is comprised of plasmid DNAs encoding distinct 
proteins, which in combination yield optimal coverage for a given number of antigens. 
These designs were subsequently modified to parallel Env modifications that have been 
previously explored as vaccine antigens, including i1CFI deletions, where i1CFI refers to 
deletions of the cleavage site, fusogenic domain, and spacing of heptad repeats 1 and 2 
(4), and gp145, to compare the impact of En v modifications relative to intact gp160 on T­
cell responses to the various antigens (Fig. I A). In addition, the three natural strains were 
selected that in combination optimize coverage of the M group, either including or 
excluding the hypervariable VI, V2, V4 and V5 regions (i1Vs). The i1Vs were optimized 
independently, and are distinct sets of proteins. We also did several exploratory 
immunizations using mosaic constructs that had the hypervariable loops removed; no 
palticular benefit was conferred (data not shown), and as these constructs were not as 
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extensively tested as the others, we did not include these results in further analysis . The 
number of mice that received each vaccine and a description of the peptide pools used in 
the analysis is shown (Table S2). 
The rationale for the deletion of the hypervariable regions is that they are often 
unique, hence would be strain-specific, and responses to these regions might divert the 
vaccine-induced immune response away from more conserved and potentially cross­
reactive regions of Env. The code for both designing mosaics and selecting optimal 
natural sequences is available on-line: 
http://www.hiv.lanl.gov/contentlsequence/MOSAICI (34). A comparison of the basic 
gp 160 vaccine designs to the M group sequences from the 2006 HIV -1 database Env 
alignment (www.hiv.lanl.gov) is shown, and the impact on numbers of potential epitopes 
lost by deleting parts of the protein in gpI45~CFI constructs is indicated (Fig. IB) . We 
included for comparison and as a positive control a polyvalent vaccine that included one 
A, one B and one C clade Env gene (Env ABC). These strains were not optimized for 9­
mer coverage, and in combination have previously been shown to elicit immune 
responses (2-4,6,14,32). 
Induction of T-cell responses with different gp160 mosaics and mosaic deletion 
mutants 
To evaluate the T-cell responses to different gp 160 mosaics, B6D2F 1IJ mice were 
immunized with plasmid DNA vaccines encoding gp160 mosaics encoded by 1,2 or 
three plasmids, one natural strain or a natural strain with deleted V regions, and compared 
to a mixture of clade A, B, C gp145s with deletions in the cleavage, furin and interhelical 
domains (~CFI) described previously (4,14). Mice (n=10 per group) were immunized 
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with a total of 15 /-lg of DNA four times at two-week intervals. Two weeks after the last 
immunization, the splenocytes from different groups of 3 immunized mice were isolated, 
pooled and stimulated by different stimulants as in all experiments in this study: 
unstimulated, 492 Env peptides PTE in 78 pools (p 1 to p78). Additional controls 
included Env ABC peptide pools, an irrelevant peptide pool control, and non-specific 
stimulants (data not shown). The CD4 and CD8 cell responses were measured using ICS 
for IFN-y and TNF-a (Fig. 2, left and right, solid and open bars respectively). The 
minimal threshold response indicated by horizontal dashed lines was defined as 2 times 
the negative control. The CD8 response to the 1 plasmid (mos 1) gp 160 mosaic was 
lower than the response to the mos 2 or mos 3 mosaics (Fig.2, right panel 2 vs. 3,4), with 
4 compared to 7 positive pools above background. Some peptide pools were shared in 
common among the three different mosaic combinations while others were unique. 
The responses elicited by the natural strain plasmids, with or without V region 
deletions, or gp l45~CFI trivalent plasmids were decreased relative to the mosaics using 
the PTE peptide pools. For example, the 3 mosaic set induced a CD8 response above 
0.25% in 7 peptide pools compared to only 2 pools with 3 natural Env's (Fig. 2, right 
panel 4 vs. 5), and these responses were higher in magnitude. Similar results were seen in 
CD4 responses (Fig. 2, left panel), though the wild type natural strain plasmid induced a 
larger number of CD4 epitope responses. The additional animals in each group were 
sacrificed and analyzed in the same way, and statistical analysis applied to the responses 
measured from the entire group (below). From the initial observation, it was clear that 
the gp160 mosaic plasm ids elicited detectable T-cell responses against PTE peptide pools 
after immunization. 
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Immunogenicity of gp160ACFI, gp160AV, gp160AVACFI, and gp145AVACFI 
mosaics 
We next tested alternative mosaic plasmids, with or without the variable region, 
LlCFI, or both deletions. These vectors were in tum compared to the multi clade Env 
gp145LlCFI vectors shown previously to improve the breadth of the Env T cell response 
compared to single strain Env immunogens (14,32). These comparisons were done as 
described above (Figs. S2-5). The resultant immune responses for the complete groups 
of ten animals were then analyzed to determine their comparative magnitude and breadth 
of response. Breadth was defined here as the number of responses to different PTE 
peptide pools. Comparing the number of responses to PTE peptides, it was evident that 
the responses in these groups immunized with deleted mosaics was lower than with the 
wild type gp160 mosaic, particularly for CD8 responses, although this result may in part 
reflect mismatches between the immunogen and assay peptides. Nonetheless, we chose 
to focus on the more immunogenic inserts, 2 and 3 set gp 160 mosaics, according to this 
criteria. 
Strength of vaccine-induced responses to Env A, B, C, PTE and PTE grouped 
peptide pools 
The analysis of immune responses of diverse immunogen combinations to many 
peptides were Limited technically by the number of animals that could be analyzed on the 
same day. In order to compare groups analyzed with different immunogens on different 
days, internal references were used, and we evaluated this data further with a second 
approach using formal statistical analysis to compare relative vaccine potency. 
Specifically, we looked at the breadth (number of epitopes) and magnitude of cellular 
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immune responses, and attempted to control for inter assay variability on samples 
analyzed on different days. To characterize the ability of different immunogens to elicit a 
vaccine response, we detetmined the vaccine effect, the magnitude and breadth of CD4 
and CD8 responses, by comparing the IFN-y and TNF-a ICS responses to the different 
peptide pools: Env ABC peptide pools, the PTE pools, and the PTE superpools (Figs. 3A, 
B). Six immunogens were compared; sets of mos 1, 2, or 3 mosaics, and the pool of three 
natural strains, with or without V regions, in addition to a negative control and a positive 
control Env A, B, C vaccine. Reassuringly, the Env ABC vaccine elicited strong 
responses to the Env ABC peptide pools. Thus the overall vaccine response tested using 
autologous peptides suggested a robust response to the matched vaccine. The response of 
CD4 cells to the vaccine was similar in both the small size and superpools, and it was 
highly significant for both IFN-y and TNF-a responses (P < 10-4). For CD8 responses to 
the Env ABC immunogens, the IFN-y and TNF-a ICS responses were highest against B 
clade pooled peptides. Among the individual A, B, and C pools, the responsiveness of 
CD8 T -cells was reflected in a rank order, B > A ~ C (paired Wilcoxon B > A, p = 
0.0005; B > C, p = 0.003). CD4 T-cell responses were more consistent across all three 
clade pools, with B ~ A > C, paired Wilcoxon B > C p = 0.009, A > C P = 0.052 (data not 
shown). 
Magnitude of vaccine~induced immunity to PTE pools and superpools 
The strength of responses to different vaccines was also assessed by measuring 
the magnitude ofT-cell responses to subgroups of the PTE peptide pools, each containing 
10 peptides. Because peptide pools were used, a strong response might reflect either an 
intense response to a single peptide in the set, or a sum of moderate or low responses to 
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several distinct peptides in the set. For CD8 cells, the strength of the observed responses 
to the mosaics was much greater than that of the naturals or the positive control (Fig. 3). 
Among the mosaics, the 2 and 3 mosaic set responses were stronger than the single 
mosaic. The overall strength of the response to PTE pools was much greater than the 
response to the Env A, B, and C pools. The gpI45~CFI immunogens induced a 
consistently weak response, which may have resulted from a loss of epitopes due to the 
deletions in the open reading frame (see Fig. IB) which then caused mismatch between 
the immunogens with regard to the number of pep tides made on the basis of the wild type 
sequence. The response profile for CD4 is quite different from that ofCD8 (Fig. 3). 
Here, the strength of the responses to mosaics and the naturals was roughly comparable, 
and there was less variation in the response of the different vaccines than in CD8 cells. 
The data suggests that the ~CFI modification may reduce the response, possibly because 
of less matching to the ICS assay peptides, but the 145~CFI modification, which 
suppressed the CD8 response, does not do the same for the CD4 response. Finally, 
vaccine-induced immunity was determined by ICS with PTE superpools. Response 
strength to the different vaccines was also assessed by measuring T-cell responses to the 
4 peptide pools including large numbers of peptides (Fig. 3). The strength estimates for 
the large peptide pools are very similar to those obtained with the small peptide pools, 
despite the fact that they were obtained from separate experiments. 
Breadth of Responses 
Vaccine breadth was assessed using date-corrected (normalized) responses to the 
78 small peptide PTE pools. Data for identical vaccines or vaccine variants on particular 
dates were pooled, and responses were deemed positive if the median response exceeded 
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a fixed threshold as described in the statistical methods. The ICS IFN-y responses in 
CD8 cells were compared among six different vaccines. 
The breadth of the mosaics responses was dramatically greater than that of the 
naturals, including both Env ABC and the three naturals selected to optimize epitope 
coverage (Fig. 4A). The mosaics all show clear spikes for numerous peptide pools. The 
number of such pools increases from 4 to 10 in the monovalent vs. the trivalent mosaics. 
The best natural set of Envs shows only two weak spikes, at pools 7 and 13. The results 
for the TNF-a ICS responses in CD8 cells were very similar, both in magnitude of the 
response and in the specific peptide pools that test positive (Fig. 4B). 
Analogous plots for CD4 IFN-y and TNF-a ICS revealed similar patterns of 
responsiveness (Fig. 5A, B). The mosaics still generated more positive responses than 
the naturals, although the difference was less striking. For example, the 2 mosaic and 3 
mosaic sets generated a vigorous IFN-y response to 15 and 14 pools, respectively, but 
three natural proteins still do quite well (10 pools each for Env ABC, Natural/). V, and 
Natural (N11N21N3). 
Although the correction for inter-assay variation improved the experimental 
consistency between experiments, the identification of positive responses was not 
sensitive to uncertainty in the strength correction. In fact, the greater breadth of CD8 
response in the mosaics was clear, even if no strength correction is used at all. With 
regard to the threshold, changes in the threshold do affect the number of positive 
responses, and these changes can affect different vaccines differently, depending on how 
many positives are near the threshold. The CD8 breadth compmisons are very robust to 
changes in the threshold; the CD4 comparisons are not as robust. Inasmuch as the 
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breadth estimate depends on a choice of threshold, and there is uncertainty as to the 
correct value, the evidence for increased CD4 breadth in the mosaics should be viewed as 
suggestive but not conclusive. 
Concordant vs. discordant synthesis oflFN-y and TNF-a 
To evaluate the qualitative nature of the T-cell response, we examined whether 
these cells synthesized either IFN-y or TNF-a alone, or both, in response to vaccination, 
the latter a surrogate for a multifunctional cytokine production. For this analysis, the 
responses were evaluated using a heatmap representation of functional CD8 responses to 
IFN-y and TNF-a, with a threshold of 0.1 (Fig. 6A). No response, a response to either 
IFN-y or TNF-a, or a response to both IFN-y and TNF-a were represented by increasing 
"heat" (pale yellow, orange, red represent negative, monofunctional, and bifunctional 
responses, respectively). Vaccines that had similar behavior in telms of responses to 
particular peptide pools are clustered together by row, and peptides pools that had similar 
patterns of eliciting response are clustered together in columns. All gp 160 2 and 3 set 
mosaics are contained in a single large cluster; i.e., they displayed consistent patterns of 
frequent bifunctional responses to particular peptide pools. The gp160 mos 1 mosaic 
responses occupied a single cluster with intermediate reactivity. A cluster for the natural 
gpI60~CFI set was also evident. All of the mosaics elicited many bifunctional 
responses; the pattern is less apparent in the naturals, although this may be due to a 
generally lower overall response. The consistency of the responses to closely related 
vaccines is apparent. Analysis of the CD4 responses with this heatmap revealed that the 
mosaics, as well as the naturals, are broadly bifunctional (Fig. 6B). Indeed, the number 
of bifunctional responses exceeds the number of monofunctional responses. The CD4 
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responses of the mosaics and the naturals were quite similar, not only in magnitude and 
breadth, but in the specific peptide pools generating a positive response. 
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DISCUSSION 
In this report, we have analyzed the ability of HI V-I mosaic genes encoded in 
single, double or triple plasmids to confer increased reactivity against T-cell epitopes 
derived from commonly circulating viruses. The peptide designs, either those in the 
mosaics or in the PTE peptides for immune assays, were based on 9 mers in Env 
sequences and were independent of MHC, either human or mouse. Initial analyses could 
therefore be performed in inbred mice where immune function can be assessed with 
greater consistency. For this analysis, we immunized mice with these plasmids or with 
previously-defined mutants derived from natural isolates and compared their ability to 
respond to T-cell epitopes that have been identified in a high proportion of naturally 
circulating strains. The study was performed in inbred mice where the effects of these 
vectors could be assessed on the background of restricted MHC haplotypes, allowing 
comparisons on a constant genetic background. These data may underestimate the ability 
of such vectors to elicit responses to a wide array of genes, given the increased MHC 
complexity in humans and non-human primates. At the same time, the possibility remains 
that Env epitopes have undergone negative selection to escape human MHC recognition, 
which would act oppositely and possibly reduce immunogenicity in humans. 
The data indicate that the mosaic vaccine antigens are able to expand the breadth 
ofT-cell responses to Env PTE. The responses appear to be greatest in animals receiving 
combinations of two- or three-mosaic inserts that give greater predicted coverage of T­
cell epitopes based on informatic analyses. Interestingly, little difference was noted 
between two or three mosaic Env immunization, possibly because of the restricted MHC 
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haplotype in mice. Whether this would hold true in nonhuman primates or humans will 
require additional testing. 
The reason for the improved immunogenicity of the Env mosaics compared to the 
optimal natural Env glycoproteins in terms of breadth and magnitude of responses may 
relate in part to the peptides used for the ICS analysis. The number of responses to three 
mosaic proteins was surprisingly enriched over the three natural strains selected to give 
optimal M group coverage. The best naturals and the mosaics were selected relative to 
the M group collection of HI V sequences in the HIV database. Comparing the gp160 
trivalent antigen designs, the set of M group Envs from the database had 44% of its 9­
mers perfectly matched in the 3 mosaic set, while 34% were matched by the 3 optimal 
natural strains (Fig. IB). This relatively modest advantage, however, seems unlikely to 
account for the profound experimental advantage seen for mosaics over natural proteins 
(Figs. 5 and 6). One possibility is that PTE peptide pools were selected in particular to 
cover 9-mers that were most common, as were the mosaics, and the relative advantage of 
the mosaics to the optimal naturals is enhanced when tracking 9-mer identities found 
among the PTE set: 3 mosaics matched 67% of PTE 9-mers, and the best naturals 
matched only 44%. The number of identical 9-mers (potential CD8+ T-cell epitopes) 
shared between a vaccine (including all antigens in a polyvalent vaccination) and a given 
peptide pool can provide a rough estimate of the potential number of CD8+ T-cell 
responses to that vaccine that could be detected by ICS using that peptide pool. The 2­
and 3-mosaic antigens match more 9-mers than the natural-sequence polyvalent antigens 
(Fig. S6). In particular, even the 2 mosaic vaccine has a higher number of9-mer matches 
(match counts) with PTE peptides than any of the natural-sequence candidates, although 
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the latter have 3 sequences each. The 3 mosaic vaccine has higher match counts than the 
natural-sequence vaccines in 70 of 78 individual pools (Fig. S6), and a large overall 
advantage (Table 83). 
A second factor is that, by design, mosaics minimize the inclusion of rare and 
unique 9-mers. In contrast, natural strains inevitably contain many unusual, type-specific 
9-mers. T-cell reactions against rare variant epitopes found in natural strains would go 
undetected in PTE-based assays, and in fact would be of little use in a vaccinated 
population. If immunodominant, they could limit the potential to stimulate responses 
with more useful epitopes with the potential for greater cross-reactivity. For mosaic 
vaccine antigen designs based on more conserved proteins like Gag (6) we were able to 
require that every single 9-mer included in a given mosaic antigen set was found at least 
3 times in the population. For the Env-based mosaics used here, however, to span 
hypervariable regions and weave together intact proteins, we were forced to require 
inclusion ofa small number ofrare 9-mers, and 3 mosaic gp160 proteins contained 128 
9-mers that were found <3 times in the M group alignment used in Fig. lB. In contrast, 
the mixture of three natural strains contained 406 9-mers found <3 times in the 
population. Similarly, the PTE pep tides are designed to emphasize the inclusion of the 
most common potential epitopes, and so have more peptides in common with the mosaic 
proteins. If any of the vaccines elicited responses specific for epitopes that are not 
included in the PTE sets, they would be missed. The natural three gp160 cocktail 
contains I ,072 9-mers that are not found among any of the PTE peptides, while the mos 3 
mosaic vaccine has many fewer, 684, so it is possible that the natural vaccine has elicited 
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a higher frequency of responses that were missed by the assay system, because they are 
specific for the vaccine strain, 
While the approach to diversification of envelope immunogens appears 
promising, it is clear that this approach will need to be combined ultimately with an 
informatic approach to optimize the response to other viral gene products, including Gag 
and possibly Nef. Whether the addition of a relatively conserved gene product such as 
polymerase can improve this response further will also require testing. It may be argued 
that the polymerase is a less effective immunogen for protection against HIV -lor SIV 
challenge because this gene product is conserved, present in low abundance, and is not 
likely to represent a viral gene product that is highly selected by immune pressure. At the 
same time, the variability of the envelope gene and the identification of T-cell escape 
mutants in nonhuman plimates and humans suggest that this gene product, as well as the 
Gag protein, is recognized and under strong selective pressure by the immune system. 
The viral Env is under further selection by antibodies, which appear to evolve during the 
course of infection and drive the generation of new mutants (13,27,28,30). 
The data here suggest that the infonnatic approach to enhancement of viral 
diversity coverage increases the immune recognition of diverse viral epitopes. Whether 
this increased recognition can give rise to improved protection remains unknown. There 
are two ways that a polyvalent mosaic might improve a vaccine: the first is in cross­
reactive protection against circulating strains, the second is the potential to block fit 
immune escape routes. The present study suggests that the mosaic concept should be 
tested further in nonhuman primate models. In particular, the SlY sooty mangabey virus 
pool may provide an opportunity to evaluate the efficacy of mosaic immunization in 
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protecting against infectious challenge. A variety ofviruses from diverse clades have 
been identified and in many cases adapted to growth in Indian rhesus macaques (1,11). 
By assembling additional viral sequences and generating SIVsmm mosaic sequences and 
relevant challenge strains, it should be possible to test whether this approach can show 
efficacy in the context of viral infection and merit further evaluation in human efficacy 
studies. 
The recent results of the STEP trial have suggested that immunization with 
recombinant adenovirus (rAd) 5 vectors shows no efficacy in humans and may have the 
potential to increase HIV acquisition in Ad5 seropositive individuals. While the basis for 
this lack of efficacy is unknown, it is clear that the induction of a T-cell immune response 
remains a desirable goal for HIV vaccines. Even in the event that broadly neutralizing 
antibody immunogens could be elicited, the likelihood that a number of circulating 
viruses would remain resistant to neutralization or the evolution of variants that would 
escape antibody neutralization would suggest that stimulatory T-cell responses could help 
to control infection and/or contain viremia. It is therefore important to recognize that the 
approach to the development of aT-cell-based vaccine that would address diverse 
relevant strains of circulating virus remains distinct from the approach to the elicitation of 
neutralizing antibodies. It is unlikely that the informatic approach derived here to address 
T -cell diversity would resolve the issues related to broadly neutralizing antibody 
immunogens but a combination of this approach and rationally designed broadly 
neutralizing antibody immunogens may improve the likelihood of containment or 
prevention of natural HIV infection. 
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FIGURE LEGENDS 

Figure 1. Schematic representation of modified HIV Env genes and comparison of 
the potential epitope coverage (9-mer matches) between different trivalent Env 
cocktails and the Los Alamos HIV Database of M group Env sequences. 
(A) The major structural features of the Env proteins used in the present study 
(gpI60, gpI60~Vs, gpI60~CFI, gpI60~CFMVs, and gpI45~CFMVs (FI, F2, F3, F4)) 
are shown. LS represents the leader sequence. VI, V2 , V3, V4, and V5 indicate the 
respective variable regions. The transmembrane domain (TM) and other major structural 
domains are shown as indicated. Various domains of En v were deleted and the modified 
Env genes were inserted into the mammalian expression plasmid pCMVIR (2,38) for 
immunization. 
(B) The Env alignment used for these comparisons is from the 2007 Los Alamos 
database, and includes one sequence from each of 1531 people, collected from all over 
the globe and aligned, including the spectrum of diversity found among known M group 
clades and recombinants. Red indicates the fraction of all 9-mers in the database set that 
are found perfectly matched in a given antigen cocktail, orange shows those that are 
matched in 8/9 positions, and yellow in 7/9 positions - some of these may be cross­
reactive. The gpI45~CFI-modified versions of these proteins, shown on the right, do not 
have as many matching potential epitopes, because sections of Env are deleted. The nat.3 
set was optimized for gp160, and is not particularly well optimized for gp 145~CFI, and 
gives comparable coverage to Env ABC in the retained regions. When the subset of 
sequences from clades A (82 sequences), B (454) or C (464) were each compared 
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separately to these M group-designed antigens, each clade behaved roughly comparably 
(within a few percent) to the full dataset results illustrated here (data not shown). 
Figure 2. CD4 and CDS T-cell responses in mice immunized with different gp160 
mosaics, natural sequences and gp145ACFI. The indicated variants of gpl60 mosaics 
and natural strain, with or without I1Vs (Fig. I), were compared to gp14SI1CFI. Percent 
positive CD4+ (left) and CD8+ (right) cells of the total T cells were measured using ICS 
for IFN-"{ (solid bars) and TNF-a (open bars). Immunization and ICS was petformed as 
described in Materials and Methods. The vaccination groups included pCMVIR with no 
insert (Control) at IS I-lg per animal, IS I-lg per animal of the gpl60 mosaic mos 1.0; 7.S 
I-lg of each plasmid in the two-plasmid groups - gpl60 mos 2.1 and 2.2; or S I-lg of each 
of gpl60-mosaics mos 3.1,3.2 and 3.3, three gpl60 natural strains, gpl6011 Vs natural 
strains, and gp 14SI1CFI clades A, Band C. Percent positive CD4+ (left) and CD8+ (right) 
cells of the total T cells was measured using ICS for IFN-"{ (solid bars) and TNF-a (open 
bars). The minimal threshold response indicated by red horizontal dashed lines was 
defined as 2 times the response from each group's unstimulated samples (un). Red bars 
indicate responses above the background, while black bars show the level of response to 
epitope pools below the background level of detection. 
Figure 3. Estimates of the magnitude of the vaccine-induced immunity based on 
ICS responses to different peptide pools: Env ABC, PTE pools and grouped PTE 
peptides. Immune responses to the indicated immunogens by (A) IFN-y and (B) TNF-a 
ICS. The figures plot the mean and uncertainty in the "vaccine effect" Vi' which is the 
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natural logarithm of the ratio of the vaccine strength to that of the negative control. Thus, 
vaccine strength goes as exp( vi); cf. Statistical Methods for details. The negative control 
is always shown on the far left, in black, and has mean value zero, by definition. The 
vaccine effect of other vaccines is measured relative to that of the negative control. The 
green "X" plotted second from the left is a positive control, where an autologous 
response to the natural strains unselected A, Band C clade strains is measured against 
peptides derived from the vaccine protein sequences. Error bars denote 
±20 uncertainties. The open circle is a negative control; the rectangle denotes gp 160; the 
filled circle, gp 145~CFI; and "X", gp 160~CFI. 
Figure 4. IFN-y and TNF-u ICS responses of CD8+ T cells to 78 PTE peptide pools 
for selected vaccine antigen designs. Immune responses to the indicated immunogens 
by (A) IFN-y and (B) TNF-a ICS. Data from all dates and modifications of basic 
vaccines are plotted. Different dates are indicated by different colors. Positive PTE 
pools, in which the median response of replicate experiments exceeds 0.1, are indicated 
by Xs. The median response for each pool is indicated by an open square. Negative 
control vaccines were uniformly negative, and so not shown. 
Figure 5. IFN-y and TNF-u ICS responses of CD4+ T cells to 78 PTE peptide 
superpools for selected vaccine antigen designs. Immune responses to the indicated 
immunogens by (A) IFN-y and (B) TNF-a ICS. Cutoff is taken at 0.05, and the vel1ical 
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axis extends only to 1.0, rather than 2.0 as before. The date and vaccine effects for all 
models were highly significant (P < 2x 1 0-7). 
Figure 6. Hierarchical clustering and heatmap for CD8 and CD4 bifunctional (IFN­
y or TNF-a) T-cell responses to the 78 PTE peptide pools. (A) For CD8 cells, no 
response (pale yellow), a response to either IFN-y or TNF-a (orange), or a response to 
both IFN-y and TNF-a (red) are indicated. White squares indicate data that is not 
available. Rows are particular experiments, columns particular peptide pools. (B) For 
CD4 cells, the same descriptions apply, but in this case only the 4 most conserved peptide 
pools have very low reactivity and so are marked with arrows. The key at the bottom 
indicates the vac/mod used; each duplicated symbol indicates a repeated experiment on a 
different date. The number of antigens in the polyvalent vaccine is indicated at the left 
on the key (e.g., a dark blue rectangle is mos.3, gp160, which was tested in 11 different 
repeat experiments). The color key/histogram shows the total number of each class of 
response, 0, 1, or 2 responses. The 6 peptide pools tested that contained the 36 peptides 
that bear the most frequent and highly conserved 9-mers are indicated by arrows 
underneath the appropriate columns, and tend to have sparse responses. Statistically 
robust clades in the dendrograms (33) are indicated by a number at the branch point. 
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SUPPLEMENTAL FIGURE LEGENDS 

Figure SI. Amino acid sequences of gp160 and mutant mosaics and best natural 
sequences. HIV-1 Env gp160 mosaic proteins were designed according to strategies 
previously described (6) and additionally described in Materials and Methods. The 
informatic mosaics were optimized as sets of one, two or three mosaics of cocktails. The 
antigen combinations were designed separately as: 1 mosaic containing mos 1; 2 mosaics 
containing mos 2.1 and mos 2.2; and 3 mosaics containing mos 3.1, mos 3.2 and mos 3.3. 
The sequence of the three natural sequences (N1, N2, N3) are also indicated. All the full­
length gp160 sequences are indicated in (A). In addition, other Env variants with ~CFI and 
gp 160~V, gp 160~CFI, gp 160~V~CFI, gp 145~CFI and gp l45~V~CFI mutations are 
also indicated (B), (C), (D), (E) respectively. 
Figure S2. gpI60~CFI mos 2 and mos 3 mosaics elicited more breadth of CDS+ T­
cell responses than gpI60~CFI single mosaic, the two gpI60~CFI natural strains 
sets and gpI45~CFI clades A, Band C. Different versions of gp160~CFI mosaics and 
natural strain (Fig. 1) were compared to gp160 mosaics and gp145~CFI clades A, Band 
C. Immunization and ICS were performed as described in Materials and Methods. The 
vaccination groups included pCMV/R with no inseli (Control) at 15 Ilg per animal; 15 Ilg 
per animal of the gp160~CFI mos 1; 7.5 Ilg of each plasmid in the two-plasmid groups 
gp160-mos 2.1,2.2 and gp160~CFI-mos 2.1,2.2; or 5 Ilg of each ofgp160-mos 3.1, 3.2 
and 3.3, gp160~CFI-mos 3.1, 3.2 and 3.3; three gp160 natural strains, gp160~CFI natural 
strains; and gp145~CFI clades A, Band C. Percent positive CD4+ (left) and CD8+ (right) 
cells of the total T cells was measured using ICS for IFN-y (solid bars) and TNF-a (open 
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bars). The minimal threshold response indicated by red horizontal dashed lines was 
defined as 2 times the response from each group's unstimulated samples (un). Red bars 
indicate responses above the background, while black bars show the level of response to 
epitope pools below the background level of detection. 
Figure S3. gp160~V~CFI mos 3 mosaics elicited similar breadth of CDS+ T-cell 
responses as gp160~CFI mos 3 mosaics but less than gp160 mos 3 mosaics. 
gp l60~CFI~V mos 3 mosaics and gp 160~V~CFI of natural strains were compared to 
gpl60 mos 2 mosaics, gpl60 mos 3 mosaics, gpI60~CFI mos 3 mosaics, gpI60~CFI of 
natural strains and gpI45~CFI clades A, Band C. Immunization and ICS were 
perfonned as described in Materials and Methods . Percent positive CD4+ (left) and CD8+ 
(right) cells of the total T cells were measured using ICS for IFN-y (solid bars) and TNF­
a (open bars). 
Figure S4. gp145~CFI mosaics showed minimal CDS+ T-ceU responses to PTE 
peptide pool. CD4 and CD8 ICS responses ofgp145~CFI mos I mosaics, gpI45~CFI 
mos 2 mosaics and gpI45~CFI mos 3 mosaics were compared with gpI45~CFI and 
gp 145~CFI~V s of natural strains, gp 160 mos 2 mosaics, gp 160 mos 3 mosaics, 
gpI60~CFI mos 3 mosaics and gpI45~CFI clades A, Band C. Immunization and ICS 
was perfonned as in Figure S2. The gpI45~CFI mos I mosaics, gpI45~CFI mos 2 
mosaics, and gpI45~CFI mos 3 mosaics demonstrated minimal CD8 responses to PTE 
peptide pools. 
Figure S5. gp160~V mosaics elicit fewer CDS+ T-cell responses than gp160 mosaics. 
CD4 and CD8 responses of gp 160~V mos 2 mosaics and gp 160~V mos 3 mosaics were 
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compared with gp 160 syn 1 mosaics, gp 160 mos 2 mosaics, and gp 160 mos 3 mosaics. 
Immunization, ICS, and labeling follows Figures S2, S3 and S4. The gp 160~V mos 2 
mosaics and gp 160~V mos 3 mosaics elicited fewer CD8 responses to PTE peptides than 
gp 160 mos 2 or mos 3 mosaics. 
Figure 86. Matched 9-mers by pool for vaccine candidates. The number of 9-mers 
that exactly match 9-mers in each vaccine candidate is plotted for each of the 78 small (6­
12) peptide pools; vaccine sequences are the full-length (gp 160) unmodified Env 
sequences. Top panel: peptide pools in numerical order. Bottom panel: peptide pools 
ranked by number of matching counts. 
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SUPPLEMENT AL TABLES 

none ~CFI gpI45~CFI Total 
mos 1 22 8 8 38 
mos 2 47 8 8 63 
mos 3 47 24 8 79 
NI-3 12 16 8 36 
NI-3~V 13 16 8 37 
Env ABC - - 36 36 
Control 44 - - 44 
Total 185 72 76 333 
Table S1. The number of plates for each combination of vaccine (row) and 
modification (column). IFN-y or TNF-a responses ofCD4+ or CD8+ T cells were 
tested for each vac/mod; thus, the number of plates is generally a multiple of four. When 
it is not, it indicates that some data sets needed to be discarded. 
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Experiment 
Vaccine TotalI 1 2 3 4 5 6 7 8 9 10 11 12I I I I I I I I I I I 
Control 

gp160 mos 1 

gp160 mos 2.112.2 

gp160 mos 3.113.2 /3.3 

gp160 NIIN2IN3 

gp160AV mos 2.112.2 

gp160AV mos 3.113.2/3.3 

3 3 3 3 3 3 3 3 3 3 3 3 36 
3 3 3 3 3 3 18 
3 3 3 3 3 3 3 3 3 3 3 3 36 
3 3 3 3 3 3 3 3 3 3 3 3 36 
3 3 3 3 12 
3 3 6 
3 3 6 
gp160AV NIIN2IN3 I 3 3 3 3 12 
gp160ACFI mos 1 3 3 6 
gp160ACFI mos 2.112.2 3 3 6 
gp160ACFI mos 3 3 3 3 3 3 18 
gp160ACFI NIIN2IN3 3 3 3 3 12 
gp160AVACFI mos 3 3 6 
gp160AVACFI N1IN2IN3 3 3 3 3 12 
gp145ACFI mos 1 3 3 6 
gp145ACFI mos 2.112.2 3 3 6 
gp145ACFI mos 3 3 6 
gp145ACFI NIIN2IN3 3 3 6 
gp145AVACFI N1IN2IN3 I 3 3 6 
gp145ACFI EnvABC I 3 3 3 3 3 3 3 3 3 3 30 
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Table 82. Experimental design of different antigens analyzed in this study. 
Numbers of mice immunized with different antigens in each of the 12 experiments were. 
All the mice in each experiment were subj ected to ICS after stimulation with the same set 
of peptide pools: 78 pools (6 to 12 peptides each) of the MHC-independent 492 potential 
T-cell epitopes (PTE) found most frequently in the sequences of circulating worldwide 
HIV-I strains; 4 superpools (114 or 148 peptides) of the 492 PTE peptides; EnvA(l54 
peptides), Env B(158 peptides), Env C( 154 peptides) from three HIV genes described 
previously (4); Ebola GP protein (167 peptides) as the negative control, no stimulation 
for backgroWld control, and phorbol myristate acetate (PMA) with ionomycin as the 
positive control. Total numbers ofmice immunized with the same vaccine analyzed by 
ICS assay in different experiments are summarized in the last column. 
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Vaccine Candidate mean median minimum 
1 mosaic (mos 1) 13.41 9.0 
2 mosaics (mos 2.1,2.2) 22.47 21.0 3 
3 mosaics (mos 3.1,3.2,3.3) 29.26 30.0 9 
3 optimal natural 19.49 17.0 4 

(Nl,N2,N3) 

3 opt. natural (nat~V N 1 ,N2, 19.38 15.5 3 

N3) 

Table 83. Match counts between 9-mers found in vaccines (gp160 unmodified) and 
PTE peptide pools. 
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